Amgen rolls out $1B investment to build new drug substance plant in NC's biopharma hotbed

Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production footprint in North Carolina.

Amgen is laying out $1 billion to build a second drug substance facility in Holly Springs, North Carolina, the company said Thursday morning.